Medication leaflets

Active substance

Results for the substance omalizumab

13 results

About this active substance

Omalizumab is a monoclonal antibody used in the treatment of severe allergic asthma and chronic spontaneous urticaria. It works by binding to immunoglobulin E (IgE), reducing the body's allergic response.

The medication is administered subcutaneously, as directed by a doctor, usually once every two or four weeks. It is important for patients to follow the treatment regimen and inform the doctor of any unusual symptoms.

Patients should be aware of potential side effects, such as injection site reactions, headaches, or respiratory infections. It is important to inform the doctor of any unusual symptoms.

Common side effects include injection site reactions, headaches, and respiratory infections. In rare cases, severe reactions such as anaphylaxis or other serious allergic reactions may occur. Patients should be informed of these risks before use.